Company intelligence / Profile preview

EMET Pharmaceuticals

New York City, New York, United Statesinvestor.eagleus.com ↗

Ownership: Private
Development stage: Other

Overview

Completed a Phase 3 bioequivalence study comparing their mesalamine delayed release tablet to Asacol® in patients with mild to moderately active ulcerative colitis. The study aimed to establish therapeutic equivalence and evaluate safety. Another similar trial was registered but not yet recruiting as of last update. No other clinical results or programs are publicly disclosed.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on EMET Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMET Pharmaceuticals.

Explore the full profile